Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2025 (Fiscal 2026 Q1 and Q2).
Business Overview: NAII operates in two primary segments: private-label contract manufacturing for nutritional supplements and patent/trademark licensing (primarily beta-alanine products under the CarnoSyn® brand). The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Net Sales | $34.8 million | $72.5 million |
| Gross Profit | $2.5 million (7.2% margin) | $6.9 million (9.5% margin) |
| Loss from Operations | $(1.8) million | $(1.6) million |
| Net Loss | $(2.6) million | $(2.8) million |
| Diluted Net Loss Per Share | $(0.42) | $(0.47) |
| Cash and Cash Equivalents | $3.8 million (as of Dec 31, 2025) | N/A |
| Debt Outstanding | $5.8 million (Line of Credit) + $8.8 million (Term Note) | N/A |
| Net Cash Used in Operating Activities | N/A | $(10.4) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% year-over-year (YoY) for the quarter and 8% YoY for the six-month period. Private-label contract manufacturing sales grew 9% over the six months, while patent and trademark licensing revenue declined 15% YoY over the same period.
- Margin Expansion: Gross profit margin improved significantly, rising from 4.9% to 7.2% for the quarter and from 5.8% to 9.5% for the six-month period. This was driven by increased sales volume improving factory utilization and favorable product mix.
- Operating Loss Reduction: The operating loss narrowed by 34% for the quarter and 66% for the six-month period compared to the prior year, despite continued net losses.
- Cash Flow Deterioration: Net cash used in operating activities increased significantly to $10.4 million for the six months ended Dec 31, 2025, compared to $3.4 million in the prior year. This was primarily due to an $8.6 million cash outflow for inventory buildup and a $3.1 million increase in accounts receivable.
- Foreign Exchange Impact: The company incurred a foreign exchange loss of $0.5 million for the six months ended Dec 31, 2025, compared to a loss of $0.3 million in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a net loss for the full fiscal year 2026 and the second half of the year, citing declines in customer forecasted sales and delayed new product launches. However, they expect revenue concentration from their largest customer to decrease in fiscal 2026.
- Liquidity and Debt Covenants: The company is currently not in compliance with the net loss and fixed charge coverage ratio covenants of its credit agreement with Wells Fargo. A waiver was obtained for the quarter ended September 30, 2025, and discussions are ongoing for a waiver for the quarter ended December 31, 2025. The lender has indicated it will not terminate the agreement. The company is also in active discussions with a potential new asset-based lender to secure a facility with greater flexibility.
- Legal Contingencies: A tentative settlement of up to $1.25 million has been reached regarding a class action lawsuit filed by former employees. The company has accrued this amount plus legal fees. Court approval is pending.
- Tax Matters: The IRS has denied a portion of the company's Employee Retention Tax Credit (ERTC) claim for Q3 2021. The company is contesting this denial. A full valuation allowance has been recorded against domestic deferred tax assets due to cumulative losses.
- Geopolitical and Trade Risks: The company monitors risks related to global conflicts and new U.S. tariffs on imported goods, which could impact the cost and availability of raw materials like beta-alanine.
Investor Verification Checklist
- Covenant Compliance: Verify the status of the ongoing waiver negotiations with Wells Fargo and the likelihood of securing a new asset-based lending facility.
- Cash Burn Rate: Assess the sustainability of the $10.4 million operating cash outflow over six months and the adequacy of the $3.8 million cash balance plus $4.2 million remaining credit line capacity.
- Customer Concentration: Confirm the stability of the top three customers, who accounted for approximately 60% of net sales in the six-month period.
- Legal Settlement: Monitor the court approval process for the $1.25 million employee lawsuit settlement.
- Inventory Levels: Review the rationale for the $8.6 million increase in inventory, ensuring it aligns with future sales forecasts and does not indicate obsolescence risk.